Nov 5, 2025 - Trond Atle Smedsrud, CEO Emerging Businesses Aker BioMarine ASA,
purchased yesterday 6500 shares in Aker BioMarine ASA at an average price of NOK
85,72 per share through his investment company HAWI Holding AS. The shares were
acquired on Oslo Børs. Following the transaction, Smedsrud holds a total of 19
789 shares in Aker BioMarine ASA.
Please see attached primary insider notification form pursuant to the
requirements of the Market Abuse Regulation ("MAR").
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Lars Jacobsen, General Counsel at Aker BioMarine
ASA, on Nov 5, 2025 at 09:49 CEST
About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops
krill and algae-derived products for consumer health and nutrition. Krill is a
natural, powerful, and health-promoting source of nutrients from the pristine
waters of Antarctica, and Aker BioMarine has a unique position in its industry.
The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine,
and PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.